Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02900560 · ClinicalTrials.gov registry record · Phase 2
Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer
A Phase 2 study, sponsored by Translational Research in Oncology.
- Terminated
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT02900560 is a Phase 2 study that was terminated before completion, run by Translational Research in Oncology. The registered enrollment target is 34 participants.
The verdict
NCT02900560, a Phase 2 study, was terminated before completion, sponsored by Translational Research in Oncology.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
The purpose of the study is to determine the optimal dose of CC-486 (oral azacitidine) in combination with pembrolizumab for the treatment of platinum-resistant/refractory Epithelial Ovarian Cancer (EOC).
Interventions
- BIOLOGICAL Pembrolizumab
- DRUG CC-486
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2016-12-20 |
| Est. Completion | 2021-05-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02900560
The ClinicalTrials.gov registry entry for NCT02900560 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Translational Research in Oncology, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT02900560 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02900560 about?
NCT02900560 is a clinical study titled "Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer". The purpose of the study is to determine the optimal dose of CC-486 (oral azacitidine) in combination with pembrolizumab for the treatment of platinum-resistant/refractory Epithelial Ovarian Cancer (EOC).
What is the current status of trial NCT02900560?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2016-12-20. Estimated completion is 2021-05-27.
What interventions are being tested in trial NCT02900560?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), CC-486 (DRUG).
Who is sponsoring clinical trial NCT02900560?
This trial is sponsored by Translational Research in Oncology, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.